As a leader in muscle biology research, we are dedicated to our mission of improving the lives of people confronting devastating diseases of impaired muscle function.
Company Provides 2018 Financial Guidance and Expected Milestones; Reduced Operating Expenses vs. 2017; Over Two Years of Cash Based on Current Burn Rate CK-2127107 Advancing in Four Clinical Trials Under Collaboration with Astellas; Results Expected in 2018 with Data from Phase 2 Clinical Trial...READ MORE ›
People fighting amyotrophic lateral sclerosis have few treatment options; we are dedicated to changing the progression of this fatal disease.
Heart failure death and disability rates continue to rise, despite current treatment options. With Amgen, we are developing a novel therapy that may improve cardiac performance in people with heart failure.
People suffering from spinal muscular atrophy experience devastating loss of muscle function. With Astellas, we are working on a treatment that may enhance skeletal muscle performance in these and other patients.